Lundbeck's idalopirdine fails in Phase III AD trial

H. Lundbeck A/S (CSE:LUN) said idalopirdine ( Lu AE58054) missed the primary and secondary endpoints in the Phase III STARSHINE study to treat mild to moderate Alzheimer's disease. Idalopirdine is a serotonin (5-HT6) receptor antagonist.

The news drove down shares of Axovant Sciences Ltd. (NYSE:AXON), whose serotonin receptor antagonist intepirdine ( RVT-101) is in a Phase III trial to treat AD. Axovant fell $2.16 (12%) to $15.14 on Thursday. ...